CellCentric secures $120 million investment

19 May 2025

Cambridge, UK-based CellCentric today announced the completion of a $120 million Series C funding round.

The clinical-stage biotechnology company is developing inobrodib, a first in class oral cancer drug to treat specific cancers, notably multiple myeloma.

Inobrodib is currently undergoing a Phase IIa study in combination with dexamethasone and Bristol Myers Squibb’s (NYSE: BMY) Imnovid (pomalidomide) for relapsed or refractory multiple myeloma. A readout from the study at last year’s American Society of Hematology meeting showed a 75% overall response rate at the highest dose level.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK